Price Chart

Executive Summary

Pulmatrix filed an S-3 registration statement to register the resale of up to 490,910 shares of common stock by selling stockholder RCM Eos PIPE HOLDINGS, LLC. These shares are issuable upon conversion of 1,000 shares of newly designated Series B Convertible Preferred Stock (conversion price $2.20/share) and as 8% annual dividend shares. The filing is a contractual obligation tied to the March 2026 private placement and the pending merger with Eos SENOLYTIX, where pre-merger Eos stockholders will own ~94% of the combined company. Pulmatrix had only $3.3M cash as of March 31, 2026, and is a pre-revenue biotech with no products, making this a routine resale registration that does not raise new capital but highlights the company's precarious financial position as it awaits merger close.

Key Facts

• S-3 registers up to 490,910 shares of common stock for resale by RCM Eos PIPE HOLDINGS, LLC, representing ~13% dilution versus the 3,652,285 shares outstanding as of May 27, 2026.
• Shares registered include 454,546 conversion shares from 1,000 Series B Convertible Preferred Shares (conversion price $2.20) and 36,364 dividend shares (8% annual dividend on stated value).
• Conversion price of $2.20 is 71% above the June 3, 2026 closing price of $1.29 — conversion unlikely unless stock rallies significantly.
• Pulmatrix had only $3.3M in cash and a $1.17M net loss in Q1 2026, with accumulated deficit of $303.5M as of March 31, 2026.
• The company is executing a reverse merger with Eos SENOLYTIX where pre-merger Eos stockholders will own ~94% of the combined company; if the merger fails, the board may pursue dissolution.
• The company will not receive any proceeds from the resale of shares by the selling stockholder.

Financial Impact

Dilution of approximately 13% from the registered shares, but the conversion price ($2.20) is well above market ($1.29), so actual dilution is contingent on a stock price rally. The company's Q1 2026 cash burn of ~$1.1M/quarter means the $3.3M cash balance provides under 3 quarters of runway without the $1M preferred stock proceeds already received.

Risk Factors

• If the Eos merger fails, the company has stated it may pursue dissolution and liquidation, given the $3.3M cash balance and $1.1M quarterly burn rate with no revenue.
• The 13% potential dilution from the registered shares could pressure the stock if the conversion price is reached.
• The stock already trades significantly below the $2.20 conversion price, suggesting limited investor confidence in the current business plan.
• The company had only $3.3M in cash as of March 31, 2026, with $1.17M net loss that quarter, implying under 3 quarters of runway.
• The merger requires approval by both Pulmatrix and Eos stockholders, Nasdaq listing approval, and SEC effectiveness — any of which could delay or scuttle the deal.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

US Market Status